Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 8.43% is 14% below its 5-year average of 9.86%, near the low end of its 5-year range (7.79%–12.56%).
As of the fiscal period ended Wednesday, December 31, 2025. 7.97% below its 12-month average of 9.16%.
Annual fiscal-year return on invested capital; no daily interpolation.
RETURN ON INVESTED CAPITAL (ROIC)
8.43%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
9.16%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
9.70%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
9.86%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
7.57%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
7.61%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
8.83%
CURRENT VS TTM AVG
-7.97%
CURRENT VS 3Y AVG
-13.05%
CURRENT VS 5Y AVG
-14.46%
CURRENT VS 10Y AVG
+11.33%
CURRENT VS 15Y AVG
+10.84%
CURRENT VS 20Y AVG
-4.50%
SECTOR MEDIAN · HEALTHCARE
8.53%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-1.17%
vs the sector median at left
Abbott Laboratories
Market Cap
$179.58B
Return on Invested Capital (ROIC)
8.43%
TTM Avg
9.16%
3Y Avg
9.70%
5Y Avg
9.86%
Market Cap
$160.55B
Return on Invested Capital (ROIC)
21.53%
TTM Avg
11.95%
3Y Avg
11.58%
5Y Avg
9.92%
Market Cap
$202.95B
Return on Invested Capital (ROIC)
13.16%
TTM Avg
11.04%
3Y Avg
11.80%
5Y Avg
12.80%
Market Cap
$211.18B
Return on Invested Capital (ROIC)
7.58%
TTM Avg
7.80%
3Y Avg
8.16%
5Y Avg
9.10%
Market Cap
$216.72B
Return on Invested Capital (ROIC)
29.53%
TTM Avg
34.26%
3Y Avg
43.03%
5Y Avg
88.96%
Market Cap
$139.86B
Return on Invested Capital (ROIC)
8.84%
TTM Avg
9.06%
3Y Avg
10.60%
5Y Avg
10.43%
Market Cap
$137.47B
Return on Invested Capital (ROIC)
4.72%
TTM Avg
4.17%
3Y Avg
4.46%
5Y Avg
4.93%
Market Cap
$134.62B
Return on Invested Capital (ROIC)
5.72%
TTM Avg
5.90%
3Y Avg
6.54%
5Y Avg
6.70%
Market Cap
$126.79B
Return on Invested Capital (ROIC)
13.90%
TTM Avg
13.75%
3Y Avg
11.92%
5Y Avg
10.17%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | $179.58B | 8.43% | 9.16% | 9.70% | 9.86% |
| Gilead Sciences, Inc. (GILD)vs › | $160.55B | 21.53% | 11.95% | 11.58% | 9.92% |
| Amgen Inc. (AMGN)vs › | $202.95B | 13.16% | 11.04% | 11.80% | 12.80% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $211.18B | 7.58% | 7.80% | 8.16% | 9.10% |
| Novo Nordisk A/S (NVO)vs › | $216.72B | 29.53% | 34.26% | 43.03% | 88.96% |
| Pfizer Inc. (PFE)vs › | $139.86B | 8.84% | 9.06% | 10.60% | 10.43% |
| CVS Health Corp. (CVS)vs › | $137.47B | 4.72% | 4.17% | 4.46% | 4.93% |
| Danaher Corporation (DHR)vs › | $134.62B | 5.72% | 5.90% | 6.54% | 6.70% |
| Bristol-Myers Squibb Company (BMY)vs › | $126.79B | 13.90% | 13.75% | 11.92% | 10.17% |
| Stryker Corporation (SYK)vs › | $126.60B | 8.53% | 10.14% | 10.34% | 10.08% |
ROIC
8.4%
ROE
10.4%
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 8.43% |
| 2024-12-31 | 9.89% |
| 2023-12-31 | 9.10% |
| 2022-12-31 | 11.36% |
| 2021-12-31 | 12.56% |
| 2020-12-31 | 7.79% |
| 2019-12-31 | 7.07% |
| 2018-12-31 | 5.35% |
| 2017-12-31 | 0.46% |
| 2016-12-31 | 4.92% |
| 2015-12-31 | 6.36% |
| 2014-12-31 | 5.06% |
| 2013-12-31 | 5.54% |
| 2012-12-31 | 3.39% |
| 2011-12-31 | 12.92% |
| 2010-12-31 | 11.49% |
| 2009-12-31 | 11.74% |
| 2008-12-31 | 14.67% |
| 2007-12-31 | 11.97% |
| 2006-12-31 | 11.04% |
| 2005-12-31 | 14.27% |
| 2004-12-31 | 13.44% |
| 2003-12-31 | 10.14% |
| 2002-12-31 | 12.35% |
| 2001-12-31 | 8.51% |
| 2000-12-31 | 21.65% |
| 1999-12-31 | 20.90% |
| 1998-12-31 | 22.42% |
| 1997-12-31 | 22.98% |
| 1996-12-31 | 22.60% |
